Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK3 | P52333 | 2/20 | 0.42 |
| ▸ | JAK2 | O60674 | 5/20 | 0.39 |
| ▸ | STAT6 | P42226 | 1/20 | 0.39 |
| ▸ | PTK2 | Q05397 | 11/20 | 0.39 |
| ▸ | CSF1R | P07333 | 2/20 | 0.39 |
| ▸ | MAP4K1 | Q92918 | 1/20 | 0.39 |
| ▸ | TTK | P33981 | 1/20 | 0.38 |
| ▸ | FLT4 | P35916 | 1/20 | 0.38 |
| ▸ | KDR | P35968 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1285557 | 0.91 | STAT6 (0.48) | JAK3JAK2STAT6PTK2CSF1R | |
| SCHEMBL1284285 | 0.80 | CDK4 (0.51) | JAK3JAK2STAT6CSF1RFLT4 | |
| SCHEMBL1284832 | 0.79 | JAK3 (0.38) | JAK3JAK2STAT6FLT4KDR | |
| SCHEMBL1284543 | 0.79 | STAT6 (0.51) | JAK2STAT6CSF1R | |
| SCHEMBL1284416 | 0.79 | JAK3 (0.49) | JAK3JAK2FLT4KDR | |
| SCHEMBL3710772 | 0.79 | JAK3 (0.47) | JAK3JAK2STAT6PTK2MAP4K1 | |
| SCHEMBL1284506 | 0.78 | CAMK2D (0.43) | JAK3JAK2STAT6CSF1R | |
| SCHEMBL1285257 | 0.78 | PTK2 (0.43) | JAK3PTK2CSF1R | |
| SCHEMBL1284917 | 0.78 | MAPK8 (0.47) | JAK3STAT6CSF1R | |
| SCHEMBL1284926 | 0.78 | CDK4 (0.40) | FLT4KDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120088753-A1 | PYRROLOPYRIMIDINES AND USED AS KINASE INHIBITORS | MEDICAL RESEARCH COUNCIL TECHNOLOGY (GB) | 2012-04-12 | — | — | US | claimed |
| US-20120088753-A1 | PYRROLOPYRIMIDINES AND USED AS KINASE INHIBITORS | MEDICAL RESEARCH COUNCIL TECHNOLOGY (GB) | 2012-04-12 | — | — | US | disclosed |
| EP-2403853-A1 | PYRROLOPYRIMIDINES USED AS KINASE INHIBITORS | Medical Research Council Technology (GB) | 2012-01-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120088753-A1 | PYRROLOPYRIMIDINES AND USED AS KINASE INHIBITORS | MARK3, MAPK8, CDK8 | JAK3 20/4885JAK2 159/4885STAT6 446/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.